Pharmacological compounds

Prescriptions at CR start

Number of evaluated patients

n = 2842

Prescriptions at CR end

Number of evaluated patients

n = 2842

Beta-receptor blockers

(% of total population; <50; 50 - 70; >70 years)

87.3; 89.2; 87.1; 86.6 (ns)^*

85.7; 87.6; 85.4; 85.1 (ns)^*

ACE-inhibitors

(% of total population; <50; 50 - 70; >70 years)

66.7; 69.3; 68.2; 61.6 (<0.01)

65.0; 66.5; 66.8; 60.2 (<0.05)

ARBs

(% of total population; <50; 50 - 70; >70 years)

7.7; 3.5; 6.6; 13.0 (<0.0001)

8.8; 5.1; 7.4; 14.5 (<0.0001)

Statins

(% of total population; <50; 50 - 70; >70 years)

79.1; 75.6; 81.3; 76.5 (ns)

79.7; 75.6; 81.8; 78.1 (ns)

ASS

(% of total population; <50; 50 - 70; >70 years)

84.2; 82.7; 85.8; 81.8 (ns)

82.2; 80.9; 83.7; 79.9 (ns)

Clopidogrel

(% of total population; <50; 50 - 70; >70 years)

56.1; 65.7; 56.7; 48.2 (<0.0001)

52.5; 60.4; 53.3; 45.2 (<0.0001)

Vitamin-K antagonists

(% of total population; <50; 50 - 70; >70 years)

13.9; 11.6; 12.7; 18.3 (<0.001)

13.1; 11.0; 11.9; 17.3 (<0.001)

Calcium channel blockers

(% of total population; <50; 50 - 70; >70 years)

10.1; 4.5; 9.7; 14.9 (<0.0001)

10.0; 3.7; 9.8; 14.9 (<0.0001)

Diuretics

(% of total population; <50; 50 - 70; >70 years)

27.1; 13.4; 25.7; 39.5 (<0.0001)

27.6; 14.2; 26.9; 38.4 (<0.0001)

Aldosterone antagonists

(% of total population; <50; 50 - 70; >70 years)

4.4; 6.7; 4.2; 3.3 (<0.01)

4.9; 6.9; 4.9; 3.7 (<0.05)

Oral anti-diabetics

(% of total population; <50; 50 - 70; >70 years)

11.3; 4.1; 11.8; 15.2 (<0.0001)

10.9; 4.1; 11.6; 14.2 (<0.0001)

Insulin

(% of total population; <50; 50 - 70; >70 years)

5.8; 2.6; 5.9; 7.7 (<0.0001)

5.7; 2.6; 5.9; 7.7 (<0.001)